<DOC>
	<DOC>NCT00338650</DOC>
	<brief_summary>The primary objective of this study is to make adalimumab available to patients suffering from moderately to severely active Crohn's Disease who have failed to respond to, lost response to, or are intolerant to infliximab, and to evaluate safety</brief_summary>
	<brief_title>Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Patient diagnosed with moderate to severe Crohn's Disease. Failed prior infliximab therapy. Patient is judged to be in generally good health as determined by the principal investigator. Previous treatment with adalimumab. Patient considered by the investigator, for any reason, to be an unsuitable candidate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>